Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).

@article{Vansteenkiste2015CilengitideCW,
  title={Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).},
  author={Johan Vansteenkiste and Fabrice Barl{\'e}si and Cornelius F Waller and Jaafar Bennouna and Cesare Gridelli and Eray Goekkurt and D M E C Verhoeven and Alexandra Szczesna and Matthew Feurer and Janusz Milanowski and Paul R G A Germonpr{\'e} and Herv{\'e} L{\'e}na and Djordje Atanackovic and Maciej Jerzy Krzakowski and Christine Hicking and Josef Straub and Martin Picard and Wolfgang H-W Schuette and Kenneth J O'byrne},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 8},
  pages={1734-40}
}
BACKGROUND This multicentre, open-label, randomized, controlled phase II study evaluated cilengitide in combination with cetuximab and platinum-based chemotherapy, compared with cetuximab and chemotherapy alone, as first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients were randomized 1:1:1 to receive cetuximab plus platinum-based chemotherapy alone (control), or combined with cilengitide 2000 mg 1×/week i.v. (CIL-once) or 2×/week i.v… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Similar Papers

Loading similar papers…